Ending trials early can cause misleading findings; study

By Staff reporter

- Last updated on GMT

Related tags: Clinical trials, Pharmacology, Pharmaceutical industry

Clinical trials that finish early due to positive treatment effects often have misleading findings, according to a journal paper which recommends researchers resist pressures to end studies prematurely.

Large, convincing differences between the effect of an experimental treatment and existing therapy can prompt researchers to end a trial, allowing all patients to take the studied drug.

Furthermore, ending a trial early can help a drug reach market sooner and be beneficial for pharma companies, doctors and researchers, according to Victor Montori, an author of the study. However, concerns have been raised that ending trials early could be detrimental to patients.

According to a paper published in the Journal of the American Medical Association (JAMA)​ truncating a clinical trial can result in misleading estimates of treatment effects. In turn, this can lead to misguided decisions about the trade-off between risks and benefits of a therapy.

Consequently, the paper’s authors, who work at a number of institutions around the globe, recommend that researchers resist ending a trial unless there is a very good reason and the study is almost over anyway.

Ending clinical trials early has been the subject of some debate and controversy​ but is regarded by the US National Cancer Institute as a valid practice​ if there are severe side effects or the study “is going particularly well​”.

Results were generated by analysing 91 truncated clinical trials asking 63 different questions and 424 matching studies that ran to completion. The analysis showed truncated clinical trials were associated with greater effect sizes, with the impact particularly pronounced in smaller studies.

Related news

Related products

show more

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 18-Apr-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more